Neutrophil‐lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non‐small‐cell lung cancer patients treated with concurrent chemoradiotherapy
- 15 June 2017
- journal article
- research article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 12 (3) , 1264-1273
Abstract
Objectives: To identify the factors that predict the progression of radiological radiation pneumonitis (RP) to symptomatic RP, and to evaluate the usefulness of the neutrophil‐lymphocyte ratio (NLR) as a marker of RP severity and prognosis in stage III non‐small cell lung cancer (NSCLC) patients treated with definitive concurrent chemoradiotherapy (CCRT).Materials and Methods: We retrospectively reviewed 61 patients treated between January 2010 and December 2015. Patients' demographic characteristics, clinical data, laboratory findings and treatment parameters were analyzed to determine the predictive factors associated with progression from radiological RP to symptomatic RP.Results: Forty‐seven patients (77%) exhibited radiological RP at a median of 78 days after radiation therapy (RT) completion, and 15 (32%) of these patients developed symptomatic RP. The interval between RT completion and radiological RP presentation was shorter in patients who progressed to symptomatic RP (P = .001); progression was highly probable if this latency period was ≤2 months (P = .002). Stage and RT technique correlated with symptomatic RP development (P = .046 and P = .046, respectively). Among dosimetric factors, a V20 (defined as the lung volume receiving ≥20 Gy) of >30% was the most significant predictor of symptomatic RP (P = .001). The NLR and C‐reactive protein level at radiological RP were higher in patients who developed symptomatic RP (P = .067 and P = .012, respectively). On multivariate analysis, a V20 >30% and an NLR at radiological RP >6 were associated with symptomatic RP development.Conclusion: The NLR at radiological RP is a useful biomarker for predicting symptomatic RP development after CCRT in stage III NSCLC patients.Keywords
This publication has 27 references indexed in Scilit:
- Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer DatabaseAnnals of Oncology, 2016
- Neutrophil–Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma After Complete ResectionWorld Journal of Surgery, 2015
- Prognostic Significance of Preoperative Neutrophil–Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete ResectionAnnals of Surgical Oncology, 2015
- Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2015
- Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 non-small cell lung cancerRadiation Oncology Journal, 2015
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2014
- The Neutrophil-Lymphocyte Count Ratio in Patients with Community-Acquired PneumoniaPLOS ONE, 2012
- Challenges scoring radiation pneumonitis in patients irradiated for lung cancerLung Cancer, 2012
- Radiation pneumonitis and pulmonary fibrosis in non–small-cell lung cancer: Pulmonary function, prediction, and preventionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systemsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995